A different bispecific, humanized IgG1 antibody that's underneath investigation is zenocutuzumab (MCLA-128), which functions by using two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by means of ADCC. MCLA-128 capabilities through a ‘dock and block’ mechanism whereby a person arm with the antibody binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/